A cardiovascular outcomes trial in subjects with ASCVD and/or risk equivalents, such as diabetes, to determine the effects of LDL-C lowering with inclisiran on cardiovascular outcomes
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2017
At a glance
- Drugs Inclisiran (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- 09 Aug 2017 According to an Alnylam Pharmaceuticals media release, the Company intends to initiate this trial in late-2017.
- 05 May 2017 According to an Alnylam Pharmaceuticals media release, The Medicines Company plans to initiate this trial in mid-2017.
- 30 Apr 2017 New trial record